The proposed University of Maryland, Baltimore (UMB) CCHI Administrative Core will be responsible for overall organization, management, decision-making, evaluation and supervising the entire range of CCHI activities to ensure highly productive research efforts. To that end the Core will focus on: 1.) facilitating communications amongst the Research Projects, Service and Pilot Cores, Opportunity Fund Management Core and Principal Investigator;2.) implementation of periodic evaluations;4.) allocating and reallocating resources to meet program goals;5.) tracking and prioritizing fiscal and other resources;and 6.) organizing presentations and publication of data. The goal of the Administrative Core is the successful implementation of UMB-CCHI goals and objectives so that the specific aims of each Project and Core may be accomplished. A key mission of this Core is to maintain a stable, flexible, yet centralized infrastructure to promote and harmonize the research conducted on human immunology. The Administrative Team brings with it breadth and depth of experience in managing large diverse grants including the current UMB-CCHI grant for the past 4 years. This same Team will work together to coordinate the activities of the CCHI Research Projects as well as the Service and Pilot Cores, and the Opportunity Fund Management Core that are meant to support and synergize the research.

Public Health Relevance

The UMB-CCHI Administrative Core Team will provide the infrastructure and leadership that will be central to the Center's success. This experienced team is prepared to manage, coordinate, and supervise the full range of Center activities with the primary goal of successful implementation of CCHI goals and objectives so that the specific aims of each research project may be accomplished.

National Institute of Health (NIH)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Maryland Baltimore
United States
Zip Code
Salerno-Goncalves, Rosangela; Rezwan, Tasmia; Sztein, Marcelo B (2014) B cells modulate mucosal associated invariant T cell immune responses. Front Immunol 4:511
Fiorentino, Maria; Levine, Myron M; Sztein, Marcelo B et al. (2014) Effect of wild-type Shigella species and attenuated Shigella vaccine candidates on small intestinal barrier function, antigen trafficking, and cytokine release. PLoS One 9:e85211
Waddington, Claire S; Darton, Thomas C; Jones, Claire et al. (2014) An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution. Clin Infect Dis 58:1230-40
Wahid, Rezwanul; Zafar, Shah J; McArthur, Monica A et al. (2014) Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B. Clin Vaccine Immunol 21:427-34
McArthur, Monica A; Sztein, Marcelo B; Edelman, Robert (2013) Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Rev Vaccines 12:933-53
Eloe-Fadrosh, Emiley A; McArthur, Monica A; Seekatz, Anna M et al. (2013) Impact of oral typhoid vaccination on the human gut microbiota and correlations with s. Typhi-specific immunological responses. PLoS One 8:e62026
Barry, Eileen M; Pasetti, Marcela F; Sztein, Marcelo B et al. (2013) Progress and pitfalls in Shigella vaccine research. Nat Rev Gastroenterol Hepatol 10:245-55
Eloe-Fadrosh, Emiley A; Rasko, David A (2013) The human microbiome: from symbiosis to pathogenesis. Annu Rev Med 64:145-63
McArthur, Monica A; Sztein, Marcelo B (2013) Unexpected heterogeneity of multifunctional T cells in response to superantigen stimulation in humans. Clin Immunol 146:140-52
Wahid, Rezwanul; Simon, Jakub K; Picking, Wendy L et al. (2013) Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a. Clin Immunol 148:35-43

Showing the most recent 10 out of 24 publications